Dr Jamie Kitt (University of Oxford, UK) and co-investigators randomised 220 women with gestational hypertension or preeclampsia 1:1 to the control group, in which the women received standard NHS care, or the intervention arm, in which self-monitored BP readings were sent to a physician who subsequently optimised BP medication for the respective participants. The primary endpoint was the 24-hour mean diastolic BP at approximately 9 months postpartum.
At 9 months, the difference in 24-hour mean diastolic BP was -5.8, favouring the intervention arm over the control arm (95% CI -4.2 to -7.4). Likewise, the difference in 24-hour mean systolic BP was -6.5 mmHg, in favour of the intervention arm (95% CI -4.2 to -8.8). “Furthermore, there were 29 BP re-admissions in the control arm and 8 BP-related re-admissions in the intervention arm, meaning that we need to treat 5 individuals to avoid 1 BP-related postnatal readmission,” added Dr Kitt.
According to Dr Kitt, the results of this trial are clinically meaningful. “A 5 mmHg improvement in BP would result in a 20% reduction in lifetime cardiovascular risk if this improvement is maintained in the long-term,” he concluded.
- Kitt J, et al. Physician optimized postpartum hypertension treatment (POP-HT) randomised trial. LB04, AHA Scientific Sessions 2023, 10–12 November, Philadelphia, USA.
Medical writing support was provided by Robert van den Heuvel.
Copyright ©2023 Medicom Medical Publishers
Posted on
Previous Article
« Comorbidity in adult psoriasis Next Article
Intensive BP intervention reduces risk of dementia »
« Comorbidity in adult psoriasis Next Article
Intensive BP intervention reduces risk of dementia »
Table of Contents: AHA 2023
Featured articles
Successful results for semaglutide in highly anticipated SELECT trial
Abelacimab substantially lowers bleeding risk compared with rivaroxaban
Online First
Pemafibrate reduces microvascular complications of PAD and T2D
Encouraging data for lepodisiran as Lp(a) lowering therapy
Nicotinamide riboside may improve walking function in PAD
Successful results for semaglutide in highly anticipated SELECT trial
Gene editing may change treatment landscape of hypercholesterolaemia
Biannual zilebesiran associated with substantial BP reductions
ARTESIA: How useful is anticoagulation in subclinical AF?
MINT: Liberal or restrictive transfusion strategy in MI with anaemia?
Abelacimab substantially lowers bleeding risk compared with rivaroxaban
ORBITA-2 confirms PCI as alternative to anti-anginal drugs in stable angina
Dapagliflozin improves cardiometabolic outcomes in MI
BP intervention saves lives of hypertensive pregnant women
Related Articles
October 25, 2023
‘LAG-time’ is promising for first-line treatment of metastatic NSCLC
© 2023 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy